StackLeaf
Stock · NSE

ZYDUSLIFE

1,150.80 8.20 (-0.71%)
Last 2 days · 15m candles10/7/2026, 22:31:13
Open: 1,162.00High: 1,162.00Low: 1,147.80Prev: 1,159.00
Positive
9
Neutral
20
Negative
1

News mentioning ZYDUSLIFE

Sentiment: +27%← All news
VERIFIEDET Markets·11d★ ON YOUR LIST
Market Trading Guide: Finolex Cables among 2 stock recommendations for Tuesday
AI summary· POSITIVE
  • ·Domestic equities closed higher on positive Asian cues, falling crude oil prices and hopes of an India-US trade deal.
  • ·Analysts recommend buying Finolex Cables.
  • ·Analysts recommend buying Zydus Wellness, citing bullish technical setups, strong moving-average support and breakout patterns with upside potential.
VERIFIEDET Stocks·11d★ ON YOUR LIST
Market Trading Guide: Finolex Cables among 2 stock recommendations for Tuesday
AI summary· POSITIVE
  • ·Domestic equities closed higher on positive Asian cues, falling crude oil prices and hopes of an India-US trade deal.
  • ·Analysts recommend buying Finolex Cables.
  • ·Analysts recommend buying Zydus Wellness, citing bullish technical setups, strong moving-average support and breakout patterns with upside potential.
VERIFIEDET Finance·14d★ ON YOUR LIST
Zydus, Sunshine to set up $20 million pharma JV in Sri Lanka
AI summary· POSITIVE
  • ·Zydus Lifesciences and Sunshine Healthcare Lanka will form a $20 million joint venture.
  • ·The new entity, Zydus Sunshine Lifesciences, will establish a manufacturing facility in Sri Lanka's Horana Export Processing Zone.
  • ·The venture aims to increase local drug production and reduce import dependency.
VERIFIEDET Finance·24d★ ON YOUR LIST
Zydus Lifesciences completes acquisition of Assertio
AI summary· NEUTRAL
  • ·Zydus Lifesciences has completed the acquisition of Assertio Holdings Inc.
  • ·The acquisition was made through its wholly-owned subsidiary, Zara Merger Sub Inc.
  • ·The transaction involved a cash tender offer for all outstanding shares of Assertio's common stock.
VERIFIEDET Finance·37d★ ON YOUR LIST
Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns
AI summary· NEUTRAL
  • ·The Delhi High Court has directed the CDSCO to review a petition against Zydus Lifesciences' semaglutide injection approval.
  • ·A diabetes patient has raised concerns regarding the drug's delivery system, citing potential health risks.
  • ·The CDSCO is required to make a decision on the patient's representation within two months.
VERIFIEDET Finance·43d★ ON YOUR LIST
Zydus Therapeutics' saroglitazar drug granted priority review by US FDA
AI summary· POSITIVE
  • ·Zydus Therapeutics' drug saroglitazar has received priority review from the US FDA.
  • ·The drug is intended for the treatment of primary biliary cholangitis, a liver disease.
  • ·Zydus Therapeutics plans to launch saroglitazar in the US in the fourth quarter of fiscal year 2027.
VERIFIEDET Finance·47d★ ON YOUR LIST
Sakar Healthcare partners with Zydus Lifesciences for GCC Markets
AI summary· NEUTRAL
  • ·Sakar Healthcare has entered into a partnership with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets.
  • ·This agreement represents Sakar Healthcare's 40th global collaboration in the anti-cancer product segment.
  • ·The company is actively pursuing regulatory filings and approvals in highly regulated international markets.